Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival
Serum vascular endothelial growth factor in epithelial ovarian neoplasms: Correlation with patient survival
复制标题
DOI：
10.1006/gyno.1999.5418
复制
发表时间：
1999-08-01
影响因子：
4.7
通讯作者：
Hsieh, CY
中科院分区：
文献类型：
--
作者：
Chen, CA;Cheng, WF;Hsieh, CY
目标。探讨血清血管内皮生长因子（VEGF）与临床病理因素的关系，探讨VEGF是否为卵巢癌患者预后的独立影响因素。56名接受手术的国际妇产科联合会I至IV期上皮性卵巢癌患者。记录临床及病理项目。采用酶联免疫吸附法测定56名妇女的血清VEGF预处理样本。结果与临床资料相关。比较组织病理学指标和血清VEGF对临床预后的影响。卵巢癌患者血清中位VEGF水平为458.7 pg/mL。75%的四分位数被定义为截止水平。治疗前血管内皮生长因子血清水平升高与56例患者较差的无病生存期（DFS） （log rank检验，P = 0.001）和总生存期（OS） （log rank检验，P < 0.001）显著相关。此外，40例残留病变小于2 cm的患者的DFS （log rank检验，P = 0.001）和OR （log rank检验，P = 0.006）也显著降低。多因素分析表明，高组织学分级（DFS组RR = 2.24， OS组RR = 2.38）和血清VEGF水平升高（DFS组RR = 3.34， OS组RR = 4.47）是56例卵巢癌患者预后的影响因素。经多因素分析，40例残留病变小于2 cm的卵巢癌患者的预后因素为手术分期高（DFS组RR = 3.28， OS组RR = 3.84）、组织学分级高（DFS组RR = 2.55， OS组RR = 2.44）、血清VEGF水平升高（DFS组RR = 5.62， OS组RR = 5.37）。预处理血清VEGF水平可作为预测卵巢癌患者预后的另一个因素。它还可以提供临床相关亚群的预后信息，例如残留病变小于2 cm的亚群。抗血管生成治疗如果可行，可能成为由VEGF等临床参数预测预后不良的卵巢癌患者的一种新的治疗方式。(C) 1999学术出版社。
Objective. To investigate the relationship between serum vascular endothelial growth factor (VEGF) and clinicopathological factors and to determine whether VEGF is an independent prognostic factor of ovarian cancer patients.Methods. Fifty-six women with International Federation of Gynecology and Obstetrics stages I to IV epithelial ovarian cancer undergoing surgery were enrolled. Clinical and pathologic items were recorded. Pretreatment VEGF serum samples of the 56 women were measured by an enzyme-linked immunosorbent assay. The results were correlated to clinical data. The histopathologic items and serum VEGF influencing clinical outcome were evaluated comparatively.Results. The median VEGF serum level in ovarian cancer patients was 458.7 pg/mL. The 75% quatile was defined as the cutoff level. Elevated vascular endothelial growth factor serum levels before therapy correlated significantly with poorer disease-free survival (DFS) (log rank test, P = 0.001) and overall survival (OS) (log rank test, P < 0.001) on all of the 56 patients. Besides, significantly reduced DFS (log rank test, P = 0.001) and OR (log rank test, P = 0.006) were also observed on 40 patients with residual disease less than 2 cm. High histologic grade (RR = 2.24 for DFS; RR = 2.38 for OS) and elevated serum VEGF levels (RR = 3.34 for DFS; RR = 4.47 for OS) are the prognostic factors on the 56 ovarian carcinoma patients by multivariate analyses. The advanced surgical staging (RR = 3.28 for DFS; RR = 3.84 for OS), high histologic grade (RR = 2.55 for DFS; RR = 2.44 for OS), and elevated serum VEGF levels (RR = 5.62 for DFS; RR = 5.37 for OS) are the prognostic factors for 40 ovarian carcinoma patients with residual disease less than 2 cm by multivariate analyses.Conclusions. Pretreatment VEGF serum levels might be regarded as an additional factor in predicting the outcome of ovarian cancer patients. It also could provide prognostic information in clinically relevant subsets, such as those of residual disease less than 2 cm. Anti-angiogenic therapy, if is available, might be a new treatment modality for ovarian cancer patients with poor prognosis predicted by VEGF and other clinical parameters. (C) 1999 Academic Press.